The 2019 American College of Cardiology Scientific Session was a robust and dynamic meeting packed with innovative research, groundbreaking science, and interactive education. Late Breaking Science including the results of DECLARE-TIMI 58, which extended the benefits of SGLT2 inhibition beyond patients with diabetes and established cardiovascular disease to those with risk factors; new data establishing the efficacy and safety of TAVR vs SAVR for low-risk patients; and data demonstrating the use of the Apple Watch for detection of atrial fibrillation shared the spotlight with many other innovative sessions. In the following pages, you will find a comprehensive review of this important meeting including topics such as primary prevention, diabetes, heart failure, vascular medicine, and p...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Next Article
DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.